LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Susceptibility Gene Identified for Idiopathic Pulmonary Arterial Hypertension

By LabMedica International staff writers
Posted on 14 Apr 2020
Print article
Image: The 96-capillary 3730xl DNA Analyzer is the Gold Standard for high throughput genetic analysis and used for Sanger sequencing (Photo courtesy of Thermo Fisher Scientific)
Image: The 96-capillary 3730xl DNA Analyzer is the Gold Standard for high throughput genetic analysis and used for Sanger sequencing (Photo courtesy of Thermo Fisher Scientific)
Idiopathic pulmonary arterial hypertension (IPAH) is a lung disorder characterized by high blood pressure in the pulmonary arteries. In this instance, “idiopathic” means that the cause of the pulmonary artery hypertension is unknown.

Pulmonary arterial hypertension is rare, with about 1,000 new diagnoses in the USA each year. IPAH is a hard disorder to diagnose because some people do not have symptoms, and when there are symptoms of IPAH, they are similar to those of other heart and lung disorders.

Scientists at the Peking Union Medical College Hospital (Beijing, China) and their colleagues enrolled 230 patients with IPAH from two referral pulmonary hypertension centers in China. Eligible patients had no BMPR2 variants and were compared with 968 healthy control participants. Data were collected from January 1, 2000, to July 31, 2015, and analyzed from August 1, 2015, to May 30, 2018.

The investigators sequenced the genomes of 42 patients with IPAH, none of whom had BMPR2 variants. The team also performed whole genome sequencing (WGS), Sanger sequencing on an ABI 3730 automated sequencer (Applied Biosystems, Courtaboeuf, France), right heart catheterization, pulmonary vasodilator testing, plasmid construction, cell culture and transfection, measurement of 6-Keto–prostaglandin F1α levels using an enzyme-linked immunosorbent assay (ELISA) kit (Cayman Chemical, Ann Arbor, MI, USA).

After filtering, the scientists uncovered 1,986 rare variants affecting 1,772 candidate genes. Most of these alterations were present only in a single person, but 15 genes were altered in three or more people. Of those, PTGIS, MACF1, GTF3C1, and ABCA3 are expressed in the lung. As PTGIS encodes prostaglandin synthase, which is involved in prostaglandin production, the team suspected it might be the most relevant of those 15 genes. In a replication cohort of 188 patients with IPAH, they uncovered additional patients with PTGIS variants. In all, 14 patients harbored one of three rare PTGIS variants.

The three rare PTGIS variants: A447T, R252Q, and c.521 +1G>A, are all located in conserved regions of the gene and are predicted by in silico analysis to be deleterious. Functional studies found that the PTGIS splicing variant affects the gene's transcription, as it led to exon skipping and an in-frame deletion. The two missense variants, meanwhile, led to impaired enzyme activity, decreased prostaglandin production, and increased cell death of pulmonary microvascular endothelial cells.

The authors concluded that they had identified three rare loss-of-function variants in the PTGIS gene from two independent cohorts with IPAH. The genetic variants of PTGIS predispose pulmonary vascular responses to the iloprost stimulation. These findings suggest that PTGIS variants may be involved in the pathogenesis of IPAH. The study was published on April 1, 2020 in the journal JAMA Cardiology.

Related Links:
Peking Union Medical College Hospital
Applied Biosystems
Cayman Chemical


Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
Total Hemoglobin Monitoring System
GREENCARE Hb
New
Piezoelectric Micropump
Disc Pump

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.